TScan Therapeutics Inc. (TCRX)
NASDAQ: TCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 11:47 AM ET
TCRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.66M
- EPS (TTM)
- -$0.91
- Dividend yield
- None
- 52-week range
- 0.224 – 2.57
- Day range
- 0.2279 – 0.2444
- Volume / Avg
- 255.71K / 783.59K
- Beta
- —
- Shares outstanding
- 63.50M
52-week range
TCRX stock today
Shares of TScan Therapeutics (TCRX) are trading higher on Oct 9 at $0.231, a gain of 1.23% or $0.0028 per share, versus the S&P 500's 0.40% gain. Shares are 91.0% below their 52-week high of $2.57, set on Oct 16, 2025 and 3.1% above the 52-week low of $0.224, near the bottom of the past year's range. TCRX is down 77.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 88.5%.
TScan Therapeutics has posted a net loss over the last twelve months (EPS of -$0.91), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About TScan Therapeutics
Company profileTScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Gavin MacBeath Ph.D.
- Headquarters
- Waltham, MA
- Employees
- 138
- IPO year
- 2021
- Website
- tscan.com
Analyst forecast
ForecastConsensus (5 analysts)
hold
Avg. price target
$1.00+332.90%
- Strong buy 0
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
TScan Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ESLAEstrella Immunopharma Inc. | 0.37 | -11.38% | $16.09M | vs TCRX |
| BCDABioCardia Inc. | 1.08 | +1.73% | $16.32M | vs TCRX |
| INABIN8bio Inc. | 1.36 | -1.25% | $13.43M | vs TCRX |
| PLURPluri Inc. | 1.00 | 0.00% | $12.61M | vs TCRX |
| DYAIDyadic International Inc. | 0.4575 | +2.96% | $18.33M | vs TCRX |
| PASGPassage Bio Inc. | 3.82 | +2.41% | $12.29M | vs TCRX |
| JSPRJasper Therapeutics Inc. | 0.5706 | +1.89% | $18.99M | vs TCRX |
| INTSIntensity Therapeutics Inc. | 3.59 | -2.45% | $11.72M | vs TCRX |
Indexes, lists and sector
TScan Therapeutics stock FAQ
What is TScan Therapeutics's stock price today?
TCRX last traded at $0.231 as of Oct 9, 11:47 AM EDT, up 1.23% on the day. Prices are delayed at least 15 minutes.
Who is TScan Therapeutics's CEO?
Dr. Gavin MacBeath Ph.D. is the chief executive officer of TScan Therapeutics Inc., which has about 138 employees.
What is the TCRX 52-week high?
The 52-week high for TCRX is $2.57 and the 52-week low is $0.224. The stock is currently 91.0% below its high.